No drug in recent memory has captured public attention like semaglutide — sold as Ozempic for diabetes and Wegovy for weight loss. The "Abnehmspritze" has become a cultural phenomenon, a dinner-party topic, and a genuine medical breakthrough all at once. But between the hype and the backlash, what does the evidence actually show?
The weight loss data
The STEP trials — the pivotal randomized controlled trials for semaglutide as a weight-loss drug — showed results that were genuinely unprecedented in obesity medicine.
In STEP 1 (n=1,961), participants receiving weekly semaglutide 2.4mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% in the placebo group. About one-third of participants lost more than 20% of their body weight — a threshold that had previously been achievable only through bariatric surgery.
These are not modest effects. For a person weighing 100 kg, that's 15 kg of weight loss, sustained over more than a year. No lifestyle intervention and no previous medication has come close to this in a randomized trial.
The cardiovascular data — this is the bigger story
Weight loss drugs have historically struggled with cardiovascular safety. Several have been pulled from the market for causing heart problems. So when the SELECT trial (n=17,604) showed that semaglutide reduced major cardiovascular events by 20% in overweight or obese adults with established cardiovascular disease — independent of diabetes status — it changed the entire conversation.
This is not just a weight loss drug. It's a cardiovascular risk reduction tool. The American Heart Association and European Society of Cardiology are both updating their guidelines to reflect this.
The side effects — honest accounting
Semaglutide is not a free lunch. The most common side effects are gastrointestinal: nausea (44% in clinical trials), diarrhea, vomiting, and constipation. These typically improve over weeks as the dose is titrated up, but for some patients they remain significant.
More concerning are the rarer adverse events: pancreatitis (rare but documented), gallbladder disease (weight loss itself is a risk factor), and a potential signal for thyroid C-cell tumors seen in animal studies (relevance to humans uncertain). There are also reports of muscle mass loss alongside fat loss — which is a real clinical concern, especially in older adults where preserving muscle is critical.
The rebound problem
The STEP 1 extension trial showed that patients who stopped semaglutide regained approximately two-thirds of the weight they had lost within one year. This is not a cure for obesity — it's a chronic medication. Patients need to understand this before starting.
Who should consider GLP-1 therapy
Based on current evidence, GLP-1 receptor agonists are most clearly beneficial for:
- Patients with BMI ≥30 (or ≥27 with weight-related comorbidities) who have not achieved adequate weight loss through lifestyle intervention alone
- Patients with type 2 diabetes — particularly those with cardiovascular disease or high cardiovascular risk
- Patients with established cardiovascular disease and obesity — the SELECT population
They are not appropriate for people seeking to lose vanity weight, bodybuilders looking for a shortcut, or anyone with a history of medullary thyroid cancer or MEN2 syndrome.
How this relates to Health Detectors
We don't prescribe GLP-1 medications — we're a diagnostic and coordination program, not a treatment clinic. But metabolic risk assessment is central to what we do. Our DETECT panel identifies insulin resistance, prediabetes, and metabolic syndrome through HOMA-IR, HbA1c, triglycerides, and liver enzymes.
If our findings suggest a patient might benefit from GLP-1 therapy, we include that in the risk report with the supporting evidence. The decision then happens between the patient and their treating physician — ideally an endocrinologist who can manage the titration, monitor side effects, and ensure muscle mass is preserved through concurrent exercise.
What we don't do is recommend it without clear clinical indication. The cultural pressure to use these drugs for cosmetic weight loss is real — but so are the side effects and the rebound data. Evidence-based medicine means recommending the drug when the evidence supports it, and saying no when it doesn't.
References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002.
- Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity (SELECT). N Engl J Med. 2023;389(24):2221-2232.
- Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide (STEP 1 extension). Diabetes Obes Metab. 2022;24(8):1553-1564.